SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The stock is facing downward pressure amid widespread community frustration regarding a prolonged quiet period, fueled by speculation that influential posters may have orchestrated a coordinated exit from their positions. While some traders view the price drop as a calculated shakeout by market makers to accumulate shares before upcoming trial results, others are expressing concern over the lack of official company communication.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending primarily due to the announcement of a new $1 billion at-the-market equity offering program, which has intensified concerns among traders regarding shareholder dilution. While some investors remain bullish on the long-term potential of the company's modular nuclear technology, others are expressing frustration over the persistent decline in stock price and the ongoing pattern of insider share sales.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a significant stock price decline, with the conversation dominated by disappointment over clinical data readouts and concerns regarding management's commercialization strategy versus potential M&A. Investors are actively debating the company's long-term valuation, the implications of recent capital raises, and whether the primary asset's efficacy metrics justify the stock's current price.

Amplify Commodity Trust - Breakwave Tanker Shipping ETF

Breakwave Tanker Shipping ETF

The Breakwave Tanker Shipping ETF is experiencing significant attention due to a prolonged surge driven by escalating geopolitical tensions in the Strait of Hormuz and the Red Sea, which have caused massive disruptions to crude oil shipping routes and forced a reliance on costlier, longer paths. Traders are actively debating whether this parabolic move will continue due to structural supply chain constraints or if it faces an inevitable correction, while many note the difficulty of shorting the asset due to limited share availability and low options liquidity.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending following a fiscal fourth-quarter earnings report that featured both a revenue and earnings beat, alongside strong forward-looking guidance driven by AI infrastructure demand. While some traders are bullish on the company's growth trajectory and sector outlook, others are expressing skepticism regarding its high valuation and the volatility of the stock's post-earnings price action.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

The community is debating the stock's transition from a bitcoin miner to an AI infrastructure and data center operator, with ongoing frustration over recent price volatility despite positive analyst price target upgrades and a significant long-term lease agreement. Traders are expressing skepticism about market manipulation and dilution concerns while maintaining divided views on whether to accumulate on dips or exit positions.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant trader attention as it maintains consolidation around key support levels, with many market participants expressing bullish sentiment regarding its role in decentralized finance, tokenization, and stablecoin infrastructure. While some observers caution about macro-economic volatility and ongoing resistance, others point to strong institutional accumulation and technical setups as indicators of future upside potential.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is trending as investors debate the project's long-term utility versus its history of price volatility, with many users highlighting the potential for institutional adoption through the Goliath mainnet and the integration of Chain's technology. Sentiment remains sharply divided, as some traders express frustration over consistent downward price pressure and alleged project mismanagement, while others characterize recent fluctuations as accumulation opportunities for a long-term hold.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors respond to bullish analyst reports and positive sentiment surrounding the commercial rollout of Auvelity, particularly following its FDA approval for Alzheimer's disease agitation. Market participants are focused on the drug's revenue potential and institutional backing, with many expressing optimism about long-term growth as the company shifts toward profitability.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Market sentiment surrounding MicroStrategy is driven by anticipation of the upcoming Senate vote on the Crypto Clarity Act, with traders divided between bullish expectations of a regulatory breakthrough and bearish concerns over potential dilution and macro-economic headwinds. While many see the stock as a key proxy for Bitcoin and expect institutional inflows, others remain critical of the company's capital strategy and share structure.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near

MoonLake Immunotherapeutics is trending following a significant stock decline triggered by mixed results from a Phase 3 study for its sonelokimab candidate in psoriatic arthritis, which failed to demonstrate clear superiority over existing therapies. Investors are expressing frustration with management's perceived lack of clear communication and recent dilutive measures, while some remain focused on the upcoming FDA filing for hidradenitis suppurativa as a primary catalyst for potential recovery.

The decline appears tied to investor uncertainty and selling pressure as the company approaches its planned U.S. FDA filing for sonelokimab, while also facing a highly competitive landscape with several already-approved treatments for hidradenitis suppurativa.

Equity

MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.


MoonLake's Psoriatic Arthritis Drug Shows Promise In Late-Stage Study

MoonLake Immunotherapeutics (MLTX) announces positive Phase 3 psoriatic arthritis trial results. Cash runway backed through mid-2028.read more...

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’

At week 16, 42.1% of patients on Sonelokimab achieved at least a 50% improvement in psoriatic arthritis symptoms, meeting the trial’s primary endpoint.


MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data  

MoonLake has consistently guided for a “mid-2026” primary endpoint readout from IZAR-1, its late-stage trial for sonelokimab in certain patients with active psoriatic arthritis. 


Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?

The consensus price target hints at a 73.4% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears

SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the first quarter.

MoonLake Immunotherapeutics' CFO Sells 39K Shares

Key PointsThe executive sold 39,120 shares on June 22...

MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa

MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa...

Why MoonLake Immunotherapeutics Stock Wilted on Wednesday

Key PointsIt aims to raise up to $200 million in the offering...

MLTX Stock Extends Pullback After Biggest Rally In Over 6 Months Following Skin Disease Trial Data — A Look At The Latest Development

The biotech firm upsized its offering to $200 million, up from the previously announced $150 million.

Bearish Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Feed

News

Sentiment

Earnings

Fundamentals

Info

MLTX News